MDT

86.18

+0.38%↑

A

114.89

+0.93%↑

VEEV

174.14

-0.8%↓

HQY

83.51

+0.14%↑

PHR.US

8.67

+8.24%↑

MDT

86.18

+0.38%↑

A

114.89

+0.93%↑

VEEV

174.14

-0.8%↓

HQY

83.51

+0.14%↑

PHR.US

8.67

+8.24%↑

MDT

86.18

+0.38%↑

A

114.89

+0.93%↑

VEEV

174.14

-0.8%↓

HQY

83.51

+0.14%↑

PHR.US

8.67

+8.24%↑

MDT

86.18

+0.38%↑

A

114.89

+0.93%↑

VEEV

174.14

-0.8%↓

HQY

83.51

+0.14%↑

PHR.US

8.67

+8.24%↑

MDT

86.18

+0.38%↑

A

114.89

+0.93%↑

VEEV

174.14

-0.8%↓

HQY

83.51

+0.14%↑

PHR.US

8.67

+8.24%↑

Search

AdaptHealth Corp

Open

BrancheGesundheitswesen

11.79 -0.51

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.58

Max

12

Schlüsselkennzahlen

By Trading Economics

Einkommen

-124M

-102M

Verkäufe

26M

846M

KGV

Branchendurchschnitt

17.527

57.05

Gewinnspanne

-11.998

Angestellte

10,900

EBITDA

-147M

24M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+4.03% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

16M

1.4B

Vorheriger Eröffnungskurs

12.3

Vorheriger Schlusskurs

11.79

Nachrichtenstimmung

By Acuity

60%

40%

298 / 349 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

AdaptHealth Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2026, 23:31 UTC

Heiße Aktien

Stocks to Watch: Nike, RH, NCino

31. März 2026, 22:35 UTC

Ergebnisse

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. Apr. 2026, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. März 2026, 23:50 UTC

Akquisitionen, Fusionen, Übernahmen

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. März 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. März 2026, 23:33 UTC

Market Talk
Wichtige Nachrichtenereignisse

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. März 2026, 23:21 UTC

Ergebnisse

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. März 2026, 23:14 UTC

Market Talk
Ergebnisse

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. März 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss Widens >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. März 2026, 22:36 UTC

Ergebnisse

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. März 2026, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. März 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. März 2026, 21:35 UTC

Ergebnisse

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. März 2026, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. März 2026, 21:33 UTC

Ergebnisse

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. März 2026, 21:32 UTC

Ergebnisse

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. März 2026, 21:28 UTC

Ergebnisse

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. März 2026, 21:26 UTC

Ergebnisse

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. März 2026, 21:25 UTC

Ergebnisse

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. März 2026, 21:24 UTC

Market Talk
Ergebnisse

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. März 2026, 21:22 UTC

Ergebnisse

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. März 2026, 21:22 UTC

Ergebnisse

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. März 2026, 21:21 UTC

Ergebnisse

Nike's Digital Channel Still Too Promotional, CFO Says

31. März 2026, 21:20 UTC

Ergebnisse

Nike CEO: Converse Remains Important to Portfolio

Peer-Vergleich

Kursveränderung

AdaptHealth Corp Prognose

Kursziel

By TipRanks

4.03% Vorteil

12-Monats-Prognose

Durchschnitt 12.38 USD  4.03%

Hoch 14 USD

Tief 9.5 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AdaptHealth Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

7.95 / 8.505Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

298 / 349 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über AdaptHealth Corp

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat